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Commutability is a property of a reference material (RM)
that relates to the closeness of agreement between results for
anRMand results for clinical samples (CSs)whenmeasured
by2 measurement procedures (MPs). Commutability of
RMs used in a calibration traceability scheme is an essential
property for them to be fit for purpose. Similarly, commut-
ability of trueness controls or external quality assessment
samples is essential when those materials are used to assess
trueness of results for CSs. This report is part 1 of a 3-part
series describinghow to assess commutability ofRMs.Part 1
defines commutability and addresses critical components of
the experimental design for commutability assessment, in-
cluding selection of individualCSs, use of pooledCSs, qual-
ification of MPs for inclusion, establishing criteria for the
determination that anRM is commutable, generalization of
commutability conclusions to future measurements made
with the MPs included in the assessment, and information
regarding commutability to be included in the certificate for
an RM. Parts 2 and 3 in the series present 2 different statis-
tical approaches to commutability assessment that use fixed
criteria related to the medical decisions that will be made
using the laboratory test results.
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Background
A challenge in laboratory medicine is that lack of agree-
ment between results among different measurement pro-
cedures (MPs)16 means that results may not be suitable
for medical decisions based on those laboratory results.
One of the contributors to lack of agreement is using
noncommutable reference materials (RMs) as calibrators
in the calibration hierarchy for clinical laboratory MPs.
In this series of articles, we consider how to decide
whether an RM has suitable commutability to be used as
a common calibrator in the calibration hierarchy ofMPs,
as a trueness control material provided by an MP manu-
facturer to verify calibration, or as an external quality
assessment (EQA) or proficiency testing sample. In this
part, we describe the common requirements for the ex-
perimental design. In parts 2 and 3, we present 2 different
statistical approaches for assessment of commutability.
Part 2 is suitable for use when an RM is intended for use
as a calibrator, a trueness control, or an EQA material
(1 ). Part 3 is suitable for use only when the RM is in-
tended for use as a calibrator (2 ).
This series of articles recognizes the terms MP and
measuring system (MS) as described in the International
Vocabulary of Metrology (VIM) (3 ). An MP refers to a
written specification for how a measurement is per-
formed, including a technical description of reagents, cal-
ibrators, equipment, instrument, and other details neces-
sary to create and operate an MS that implements those
specifications. An MS is a physical in-vitro diagnostic
(IVD)medical devicemanufactured according to theMP
specifications and used tomakemeasurements on clinical
samples (CSs) to produce results (quantity values) that
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are used in research and to make medical decisions for
patient care. For example, hundreds of the same MS can
be manufactured as an implementation of a single MP;
the MSs are used by different clinical laboratories to pro-
duce results for CSs. Another example of an MS is one
developed by a clinical laboratory that is an implementa-
tion of an MP developed by that laboratory for its own
use (frequently called a laboratory-developed test). Re-
sults for an RM and for CSs measured using different
MSs are used to assess commutability of an RM. The
conclusion regarding commutability is assumed to be ap-
plicable to all other MSs that are implementations of the
same MP. For simplicity, in this series of reports we use
the term MP when referring to either an MP or results
from a specific MS that is an IVD medical device repre-
sentative of the MP.
Differences in results amongMPs may be because of
the following sources of error: (a) variation within runs,
including trends, caused by variation in performance
conditions; (b) variation between runs caused by random
error in establishing the calibration response function
and interaction between performance conditions and cal-
ibrator properties; (c) errors in the assigned values of cal-
ibrators; (d ) an unsuitable calibration model, for exam-
ple, a linear model when the relationship between
response and concentration (i.e., amount of substance
present or other quantity value) is nonlinear; (e) differ-
ence in response to influence quantities between the cal-
ibrators and the CSs intended to be measured (this dif-
ference causes a different relationship between signal and
concentration for calibrators than for CSs that is a sys-
tematic error referred to as noncommutability of the cal-
ibrator; see later definition); (f ) differences in response to
influence quantities that differ among CSs, referred to as
sample-specific effects; and (g) differences in selectivity
for the measurand.
When we compare results for CSs measured in 1
run with 2 MPs, as in a commutability assessment,
we can only estimate the combined effect of the error
sources b through e. The error sources c through e
contribute to systematic differences in results for CSs
between MPs. The systematic difference (bias) be-
tween 2 MPs can be expressed by a constant or a func-
tion of the concentration.
The effects of error sources e, f, and g above de-
pend on the selectivity of the MPs for the measurand.
Error source e contributes to the noncommutability of
an RM intended for use as a common calibrator for a
number of MPs and is the subject of this report. If an
RM is commutable with CSs in the measurement re-
sponses of MPs, the RM can be used in the calibration
traceability schemes for the MPs to reduce the system-
atic differences among the results for CSs to produce
equivalent results for CSs, within stated limits, irre-
spective of the MP used.
The sample-specific effects in error source f above
may be a confounding issue in assessing commutability of
an RM. If we consider a specific CS, the sample-specific
error can be considered as systematic (it cannot be reduced
by repeatedmeasurements), but in a population of CSs, the
sample-specific errors of individual CSs appear as random
variability to whichwe can assign an SD.Consequently, the
magnitude of sample-specific effects can influence a com-
mutability assessment and can be estimated in the experi-
mental design in part 2 of this series (1).
Deﬁnition of Commutability
The VIM defines commutability as a property of an
RM, demonstrated by the closeness of agreement be-
tween the relation among the measurement results for
a stated quantity in this material, obtained according
to 2 given MPs, and the relation obtained among the
measurement results for other specified materials (3 ).
For medical laboratories, other specified materials are
the CSs intended to be measured, and the quantity is
usually referred to as the measurand. The CSs may
come from healthy volunteers, patients visiting a
clinic, or patients with disease. The definition of com-
mutability of an RM concerns 2 MPs. When applied
to a calibration traceability scheme as described in ISO
17511, IVD medical devices—Measurement of quanti-
ties in biological samples—Metrological traceability of
values assigned to calibrators and control materials, the
definition is applicable for each combination of 2 MPs
used in the traceability scheme. However, when the
definition is applied to an RM intended for use by
several different MPs for a measurand, the experimen-
tal design for commutability assessment should in-
clude all MPs for which an RM is intended to be used.
Commutability can be stated as a property of an RM
that indicates how well an RMmimics the characteristics
of typical CSs in an MP for a stated measurand. Com-
mutability is important for RMs used in a calibration
hierarchy to ensure that the results for CSs measured in
clinical laboratories will be equivalent irrespective of the
MP used. Equivalent means within limits determined by
the medical requirements for use of a laboratory test re-
sult in a patient care decision.
The VIM definition of measurand (the quantity in-
tended to be measured) has limitations when applied to
assessment of commutability. The chemical species being
measured is the important consideration when selecting
samples or qualifying MPs for inclusion in assessing com-
mutability of an RM. In some cases, more than 1 chemical
species may be measured either intentionally or be-
cause of poor selectivity of an MP. EQA data from
commutable samplesmay identifyMPs that donotmeasure
the same quantity. Alternatively, the subgroups in an EQA
scheme may represent an inadequately defined measurand
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in the EQA material. In such situations, the quantity to be
measured may need to be more clearly defined.
Assessment of Commutability
Assessment of commutability requires the following
steps: (a) obtain RM(s) to be evaluated; (b) obtain repre-
sentative CSs; (c) measure the RM(s) and CSs using the
MPs included in the commutability assessment; and (d )
apply a procedure to evaluate the commutability of the
results for RM(s) in relation to the results for the CSs.
Currently available procedures to assess commutability
use criteria based only on the statistical distribution of
differences in results for CSs between 2 MPs; thus, the
criteria can be different for different pairs of MPs with
different precision performance (4, 5 ). Criteria for com-
mutability assessment should be the same for all MPs in
an assessment and should be based on the influence of
differences between RM and CSs on medical decisions
made using the laboratory test results. The statistical ap-
proaches in parts 2 and 3 in this series present commut-
ability assessment procedures that can use criteria based
on medically relevant differences in results between an
RM and CSs (1, 2 ).
An example of commutability assessment based on
the approach in part 2 of this series is shown in Fig. 1.
The bias between 2 pairs of MPs (x and y; x and z) is
shown for a panel of CSs and for 5 candidate RMs. The
relative bias is constant over the concentration interval
for the CSs; consequently, the average bias of the CSs is
suitable for assessment at each of the RM concentrations
examined. The error bars for each RM indicate the un-
certainty of the difference in bias between that RM and
the average bias of the CSs. The uncertainty consists of 2
components: the uncertainty of the estimate of bias for
the CSs and the uncertainty of the estimate of bias for
each RM.
The blue dashed lines in Fig. 1 indicate the prede-
terminedmaximum allowable bias for the commutability
of the RM to be considered sufficient to fulfill medical
performance requirements for its intended use. The cri-
terion is the same for all pairs of MPs examined. An RM
is commutable when the bias of the RM including the
error bars is completely within the blue dashed lines. In
Fig. 1A, RM1, RM3, and RM5 are commutable with the
CSs because their bias, including the error bars, is within
the blue dashed lines. RM2 and RM4 are not commut-
able with the CSs because the error bars are completely
outside the blue dashed lines. In Fig. 1B, the criterion is
the same because it is based onmedical use requirements.
However, there is more scatter in the CS results, suggest-
ing MP z has a larger random error component. The
increased scatter is reflected in larger error bars that now
make the commutability of RM1, RM2, and RM5 inde-
terminate because the error bars are outside of the blue
lines. The assessment of commutability illustrated in the
Fig. 1 example reflects data from CSs andMPs that qual-
ified to be included in the assessment as described in
sections that follow.
Individual CSs for Assessment of
Commutability
Individual CSs are the matrix that a clinical laboratory
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Fig. 1. The bias for logarithmic transformation of concentra-
tion [ln(concentration)] between 2 measuring systems is
shown for a panel of CSs (black diamonds) and for 5 candi-
date RMs (red squares) vs themean concentrationmeasured
with each MP.
The error bars for each RM indicate the uncertainty of the differ-
ence in bias between each RM and the average bias for the CSs.
The bias values for ln-transformed results can be multiplied by
100 togive anapproximatepercent bias. Theblack solid line is the
meanbias (18%) for all theCSs. Thebluedashed lines indicate the
maximum allowable commutability-related bias for the RM to be
considered commutable with the CSs. (A) shows results for 2MPs
(x and y) for which the random errors of the MPs and the sample-
speciﬁc inﬂuences are reasonably small. (B) shows results for 2
MPs (x and z) withmore scatter for the CS results, suggesting that
MP z has poorer precision and/or larger sample-speciﬁc inﬂu-
ences in relation to MP x.
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ideal samples to establish the relationship between differ-
ent MPs. A commutability assessment is intended to
qualify an RM as suitable for use as a calibrator, trueness
control material, or EQA sample. A commutability as-
sessment is not intended to evaluate the selectivity of
MPs for themeasurand. Inmost cases, an RM is intended
to simulate the types of CSs commonly encountered
when measuring a given measurand.
CSs should be selected with consideration of MP
selectivity limitations. The influence of interfering sub-
stances in an individual CS canmake it unsuitable for use
in a commutability assessment. CSs should be excluded
that are known to contain interfering substances or un-
usual molecular forms, such as found in less common
pathologic conditions, when these affect all ormost of the
MPs in a study. Sourcing more CSs than the minimum
needed for statistical assessment is recommended to en-
sure that enough usable data will be available to meet the
statistical requirements for a study. The presence of an
interfering substance or unusual molecular form in a CS
may not be known until identified as an outlier result in
data analysis.
Note that qualification of MPs to be included in a
study (see subsequent section of this report) should be
done before setting requirements for exclusion of CSs
so that MPs with inadequate selectivity will not com-
promise the usefulness of the evaluation of commut-
ability of an RM. In some EQA applications, an RM
may contain an uncommon molecular form for the
purpose of challenging the selectivity of MPs. Such
special cases are outside the scope of the usual purpose
for a commutability assessment and are not addressed
in these recommendations.
The interval of concentrations (quantity values) of
themeasurand in CSsmust include that of the RM(s) but
does not need to cover the entire measuring interval for
the MPs included in the commutability assessment. The
number of CSs needed will vary with the experimental
design and the performance characteristics of the MPs in
the commutability assessment. For measurands that have
large differences in measuring interval for different clin-
ical uses, for example, C-reactive protein, commutability
assessment may be restricted to 1 of the intended use
intervals or may require separate experiments for each
interval. The concentrations for the RM(s) and CSs must
be within the measuring intervals of the MPs included in
an assessment.
CSs must be collected and aliquots prepared, stored,
and distributed such that no alteration of the measurand
or matrix occurs. For practical reasons, it may be neces-
sary to store samples before a commutability assessment.
Use of preservatives, freezing or other storage condi-
tions, pooling, or any modification to an individual
CS may affect commutability and should be evaluated
for suitability in a preliminary experiment. Some mea-
surands in CSs are not stable for prolonged times un-
der defined storage conditions. Such situations need to
be considered in the experimental design for a com-
mutability assessment. Aliquots of individual CSs used
for a commutability assessment should be retained
when possible to use for commutability assessment of
new MPs or MPs that were excluded because they
required improvement in performance.
Pooled CSs for Assessment of Commutability
Although individual CSs are preferred for a commutabil-
ity assessment, sufficient volumes of individual CSs can-
not always be obtained to enable aliquoting for distribu-
tion and measurement by all MPs in a commutability
assessment. In this case, using pooled CSs instead of sin-
gle donations is a practical solution that may reduce the
cost and complexity of a commutability assessment.
Pooling dilutes the influence of a substance present in an
individual donor sample. Pools prepared from many sin-
gle donations are more likely to reduce the influence of a
few individual donors with sample-specific effects. Con-
sequently, pooled samples cannot be used to assess
sample-specific effects in the statistical analysis.
When preparing pools, the individual donors should
meet the same requirements as described for individual
CSs used alone. A preliminary experiment should be per-
formed to demonstrate that pooled CSs and their storage
conditions are suitable surrogates for individual CSs.
Pooled CSs may have matrix alterations that cause them
to be noncommutable with individual CSs. Conse-
quently, pooled CSs should be validated to be commut-
able with individual CSs before being used for commut-
ability assessment of RMs. Demonstrating that some
pools are commutable does not guarantee that other
pools prepared in the same manner will also be commut-
able, but it is a reasonable assumption. When sufficient
volume of donor samples is available, Clinical and Labo-
ratory Standards Institute document C37 (6 ) includes a
validation scheme to demonstrate commutability of a
pool based on recovery of a value expected from the pro-
portion of each donor sample used to prepare the pool.
When pooled CSs are used for commutability assess-
ment, their preparation and qualification must be fully
documented.
RM(s) to Include in an Assessment of
Commutability
Candidate RM(s) intended for use as calibrators in a cal-
ibration hierarchy (7 ), as trueness control materials, or as
EQA samples are typically produced by an organization
that assesses their commutability as part of the qualifica-
tion for intended use.When RMs are intended to be used
after dilution to obtain quantities within the measuring
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interval of the MPs, the diluted RMs must be evaluated
for commutability. The manufacturer of an RM that is
intended to be diluted before use should provide instruc-
tions for making the dilutions that address compatible or
incompatible diluents and other known influences that
could affect the performance of the diluted RM.
RMs intended to be used as common calibrators by
different MPs must be commutable. However, product
calibrators (end-user calibrators) that are provided by an
IVD manufacturer intended for use only with a specifi-
cally identified MP are not required to be commutable.
When necessary, the value assignment of such product
calibrators can compensate for a known and constant
noncommutability bias such that patient results from
that specific MP are traceable to higher order references.
Such calibrators are validated and intended for use only
with MPs specifically identified by the IVD manufac-
turer and are not intended to be used with any other MP.
Qualiﬁcation of MPs for Inclusion in a
Commutability Assessment
Cooperation with manufacturers of MPs is important
during RMdevelopment to anticipate andminimize pos-
sible constraints related to an assessment of commutabil-
ity. An MPmanufacturer may be an IVDmedical device
manufacturer or a laboratory that develops its ownMP. It
is desirable to include as many different MPs and analyt-
ical measurement principles as possible in a commutabil-
ity assessment. However, it may not be possible to in-
clude all MPs in a commutability assessment. Including
the most representative group of MPs will improve the
likelihood of an RM being suitable for use with other
MPs not included in the initial assessment or with a new
MP that may enter the market. Considerations for inclu-
sion include market share for commercially available
MPs and types of analytical measurement principles. For
laboratory-developed tests, inclusion can be based on
methods used on a large scale or offered as a service to
other laboratories. Themanufacturer of anMP is respon-
sible to ensure that an RM is commutable and suitable for
use in a calibration hierarchy.
MPs to be included in a commutability assessment
must have acceptable performance characteristics as de-
scribed below. Improvement of some MPs may be a re-
quired precursor to inclusion in a commutability assess-
ment. AnMPmanufacturer may require substantial time
to improve an MP and may have to make provision for a
follow-up commutability assessment of an RMwhenMP
improvements have been addressed.
MP PRECISION
MPs must have adequate precision because inadequate
precision can inappropriately influence assessment of
commutability. For example, a value for a measurand
from an MP with inadequate precision will have larger
uncertainty that could compromise assessment of com-
mutability for that MP. There are no fixed guidelines for
adequate precision. Considerations for acceptable preci-
sion will be determined by the experimental design that
in turn will be influenced by the criteria for acceptable
commutability, availability of CSs with sufficient volume
for replication, and cost for distributing materials and
making measurements. The desired closeness of agree-
ment between RM and CSs that needs to be identified in
the commutability assessment should be determined, and
the required precision of MPs can be estimated based on
statistical power analysis. The replication of measure-
ments is an experimental design detail that can be ad-
justed to reduce random error.
MP SELECTIVITY
MPs to be included in a commutability assessment must
have adequate selectivity for the measurand. MPs with
inadequate selectivity could inappropriately disqualify an
RM that may be suitable for use with many MPs being
used by clinical laboratories. Inadequate selectivity is
identified as bias in an individual CS, called a sample-
specific effect, that is greater than the typical bias for
other CSs and is caused by the influence of substances
other than the measurand on the measurement signal, or
by differences in response to the measurand by different
MPs. A sample-specific effect is a systematic error (bias)
for an individual CS that can be considered a random
component of bias within a group of CSs that cannot be
reduced by replication or calibration.
The selectivity of MPs for which the RM will be
used must be considered when determining whether ad-
equate commutability can be demonstrated. It may not
be possible to demonstrate adequate commutability of an
RMwith anMP that has excessive sample-specific effects.
The MP manufacturer will need to improve the selectiv-
ity for the measurand to enable the RM to be suitable for
use with that MP. Ideally, inadequate selectivity will be
identified in a qualification assessment or a preliminary
experiment. However, the nonselectivity may not be rec-
ognized until the commutability assessment is per-
formed, in which case results for that MP should be ex-
cluded from a commutability assessment of an RM for
other MPs for which the RM may be suitable for use.
Selectivity of an MP can be concentration-
dependent, for example, if different molecular forms of
an analyte are produced in disease conditions. An exam-
ple of a selectivity limitation is the presence of molecular
forms that may not be measured in a consistent ratio by
different MPs. MPs that recover the same ratio can be
included; others may need to be excluded until they can
be modified to recover the same ratio. An expert group
may need to determine which molecular forms and ratios
are appropriate for the medical use of the laboratory test.
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Criteria to Determine That an RM Is
Commutable
The intended use of an RM will influence the choice of a
criterion for commutability. The criterion for commut-
ability of an RM relates to the allowable bias for an indi-
vidual CS result (8 ). Several approaches to determine the
allowable bias for a CS result have been described that
consider the risk of harm to a patient from medical deci-
sions based on uncertainty in a measurand result for a CS
(9 ). The criterion for commutability for an RM intended
for use as a calibrator in a calibration hierarchy for anMP
should be a fraction of the uncertainty required at the
relevant position in the hierarchy to achieve the allowable
bias in a CS result.
EQA or trueness control materials are usually in-
tended to verify (not establish) that an individual result is
within an acceptable measurement error. The criterion
should consider that EQA and trueness control materials
are usually measured in singlicate or a few replicate mea-
surements. Consequently, both bias and imprecision can
influence a measured value. The criterion for commut-
ability should be a fraction of the bias component of the
acceptance limits for evaluating an EQA or trueness con-
trol result.
Closeness of agreement is a relative term, and some
RM results may have closer agreement with results for
CSs and, thus, better commutability for some MPs than
for others. A criterion based on the intended medical use
of laboratory test results is preferred but needs to be es-
tablished with consideration ofMP performance capabil-
ity. The criterion for a conclusion that an RM is com-
mutable based on medical requirements should be
established at the beginning of a commutability assess-
ment. If no available RM can meet the criterion, the
criterion may be reconsidered to permit production of an
RM that when used in a calibration hierarchy substan-
tially improves agreement of results for CSs among dif-
ferentMPs such that medical decisions are improved and
the risk of harm to a patient is reduced.
CRITERIA RELATED TO MP PERFORMANCE CHARACTERISTICS
Criteria based on statistical distribution of CS results
between MPs are less desirable and not recommended
because they can produce different criteria for different
combinations of MPs for the same measurand. Criteria
based on statistical distribution of CS results may be un-
reasonably small or large compared with the intended
medical use of laboratory test results. Criteria based on
statistical limits expect some fraction of RM–MP combi-
nations to fail to meet the criteria that could cause an
erroneous conclusion regarding the RM being fit for pur-
pose. However, a criterion related to achievable perfor-
mance of available MPs may be acceptable if the same
criterion is used for all MPs in a commutability
assessment.
In some cases, practical limitations in study design
(e.g., limited number of replicates or limited number of
CSs) and/or the performance capability of all or many
MPs (e.g., poor precision or high susceptibility to
sample-specific effects) could produce large uncertainties
that could cause high rates of inconclusive commutability
decisions and limit the ability to make a decision about
suitability of an RM (10, 11 ). In such situations, using a
less stringent acceptance criterion accounting for the
study design and performance capability of MPs can be
considered. In this situation, the claimed use of the RM
should be reconsidered accordingly.
CRITERIA FOR A SET OF CALIBRATORS
Criteria for a set of calibrators intended to be used to-
gether to cover a measuring interval need to be consid-
ered as a group. When different concentrations of RMs
are prepared independently, each RM should be inde-
pendently evaluated for commutability. If RMs are pre-
pared by a process such as admixing 2 concentrations or
another approach that provides common characteristics
between the materials, then each RM concentration may
have the same or similar relationship (i.e., bias) when
compared with the results from CSs. In this case, the
commutability of the RM may be considered as a set. If
the variability of results [i.e., SD, CV, SD(log)] for an
MP is different at different measurand values (concentra-
tions), then the data may need to be partitioned accord-
ingly (readers may refer to Clinical and Laboratory Stan-
dards Institute document EP09 for procedural details on
partitioning) (12 ). Criteria based on medical require-
mentsmay be different at different concentrations (quan-
tity values).
FRACTION OF MPs FOR WHICH A RM IS COMMUTABLE
A number of MPs will be included in the assessment of
commutability of an RM. Ideally, an RM will be com-
mutable for all MPs that it might be used with. However,
this goal is not always achievable, and in many cases there
will be some MPs for which the RM is not commutable.
An RM intended for use as a common calibrator should
be commutable for a sufficient fraction of MPs that an
improvement in medical decisions will occur. Similarly,
when an RM is intended to be used as a trueness control
or an EQA sample, its commutability should be suitable
to obtain useful information on trueness and perfor-
mance for most of the laboratories and MPs that use the
RM.
There are no simple recommendations for the frac-
tion of availableMPs for which an RMmust be commut-
able that would qualify an RM as being fit for purpose.
Considerations include the market share for MPs and
consequently the number of tested individuals who may
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be affected. Note that market share can be different in
different regions of the world. Another consideration is
the overall health improvement that would follow from
use of an RM in a calibration hierarchy even if it failed the
preestablished criteria for commutability for some frac-
tion of MPs in use. In such a case, the criteria could be
reconsidered based on the impact onmedical decisions of
using a less stringent criteria.
Generalization of Commutability of an RM to
Future Measurements
The conclusions from a commutability assessment are
strictly applicable to only the MPs and measurement
conditions (reagent lot and other parameters) used in the
experiment. It may be possible to use several reagent lots,
calibration events, and IVD medical devices of the same
MPs in a commutability experiment, but in many cases
such duplication is not realistically achievable. The ex-
periment typically assumes that the MPs and measure-
ment conditions are representative of those that will be
encountered in medical laboratories and that the conclu-
sions regarding commutability of an RM will be main-
tained when used with other IVD medical devices of the
sameMPs, as well as for other reagent lots and measuring
conditions in the future. The assumption is accepted as
reasonable in laboratory medicine, but users should keep
inmind that changes in reagents or measuring conditions
can occur that could make conclusions from a commut-
ability assessment no longer applicable. The more sub-
stantial a change, such as a change in reagent formula-
tion, the greater is the risk that commutability
conclusions may no longer be valid. In such cases, a com-
mutability assessment should be repeated to ensure that
an RM remains suitable for its intended use.
Information on Commutability to Be Provided
to the User of an RM
Table 1 includes the information regarding commutabil-
ity assessment that should be documented for a certified
RM, trueness control material, or commutable EQAma-
terial. The certificate of analysis should include a sum-
mary of the Table 1 information with details at the dis-
cretion of the RM manufacturer. All the information
must be provided on request to users of an RM. It is
recommended that the results of a commutability assess-
ment for an RM intended to be used in a calibration
hierarchy or as a trueness control be published in a peer-
reviewed journal.
Conclusion
This report provides recommendations for critical com-
ponents of the experimental design for commutability
assessment, including selection of individual CSs, use of
pooled CSs, qualification of MPs for inclusion in the
assessment, establishing a criterion for the determination
that an RM is commutable that is the same for all MPs
and is related to how a test result is used in medical
decisions, generalization of commutability conclusions
to future measurements made with the MPs included in
the assessment, and information regarding commutabil-
ity to be made available to a user of the RM and included
in the certificate for an RM.
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Table 1. Information to be included in the documentation
of an RM that is commutable for a stated number of MPs.
• Selection criteria for individuals from whom CSs were
obtained for the commutability assessment
• Number of CSs used in the commutability assessment
and their collection, processing, storage, and
distribution conditions
• Description of the experimental design used to
assess commutability; state the reference MP if
included in the experimental design
• Criteria used to conclude that an RM was
commutable with clinical samples
• Summary of the results of the commutability
assessment in sufﬁcient detail that the conclusions
can be veriﬁed; complete experimental results and
data analysis must be available to a user on request
• MPs for which commutability was demonstrated,
including the speciﬁc models of instruments and the
part numbers and lot numbers of reagents,
calibrators, and calibration conﬁrmation materials
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